Magnikor - instructions for use, reviews, analogs and formulations (75 mg tablets, 150 mg Forte) for the treatment and prevention of strokes, heart attacks, angina in adults, children and pregnancy. Composition

In this article, you can read the instructions for using the drug Magnikor. Comments of visitors of the site - consumers of this medication, as well as opinions of doctors of specialists on using Magnikor in their practice are presented. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues of Magnikor in the presence of existing structural analogs. Use for the treatment and prevention of strokes, heart attacks, angina pectoris in adults, children, as well as during pregnancy and lactation. Composition of the preparation.

Magnikor - is a combined preparation containing in its composition Acetylsalicylic acid and magnesium hydroxide.

Acetylsalicylic acid, which is part of Magnikor, has anti-inflammatory, antipyretic, analgesic and antiplatelet effect. The main pharmacological effect of this substance is the inhibition of prostaglandin and thromboxane synthesis. An additional analgesic effect is due to inhibition of COX. The anti-inflammatory effect is achieved by inhibiting the formation of PGE2 and, as a result, a decrease in the intensity of blood flow.

Acetylsalicylic acid causes an irreversible suppression of the formation of prostaglandins of the G / H classes. This influence on them continues even when the drug has already emerged from the body as a whole. This effect is due to the action of acetylsalicylic acid on the synthesis of thromboxane in the platelets. Clinically, this action is expressed in an increase in bleeding time. Normal bleeding only over time - when new platelets are formed.

The magnesium hydroxide contained in the preparation acts as an antacid agent, and also as a factor,Protecting the stomach and intestinal mucosa from the irritating effect of an aggressive acetylsalicylic acid.

Composition

Acetylsalicylic acid + Magnesium hydroxide + auxiliary substances.

Pharmacokinetics

After taking Magnikor, the active substances are rapidly absorbed into the mucosa of the gastrointestinal tract. In the event that reception of a preparation has occurred after reception of nutrition, its absorption decreases. There is also a decreased absorption of the drug in people prone to migraines. It is noted that the drug is absorbed better in patients suffering from achlorhydria, as well as in those who take antacids and polysorbates. The maximum concentration of Magnikor in the blood is observed approximately in half an hour - two hours after the administration.

Magnesium is slowly and in small amounts absorbed in the small intestine.

Acetylsalicylic acid binds well to plasma proteins. The percentage of binding is approximately 80-90%. Linked salicylates are transported by plasma proteins throughout the body. They penetrate the placental and blood-brain barrier, and also enter breast milk during the period of feeding.Magnesium is bound by plasma proteins worse (the percentage of bound magnesium is 25-30%). It is able to pass through the placental barrier.

In the body, acetylsalicylic acid is metabolized to its active metabolite, salicylate, in the gastric mucosa. After absorption, acetylsalicylic acid is quickly transformed into salicylic acid, however, within the first 20 minutes from the moment of administration, the unchanged active substance prevails.

Metabolized to the final products of salicylate mainly with the help of the liver. The average half-life is approximately 2-3 hours. At a sufficiently high dosage of Magnikor taken, the half-life period increases to a day or more. Unchanged, salicylate is also excreted in the urine, and the amount of acid depends on the level of acidity. If the reaction is alkaline, then up to 30% of the unchanged metabolite is excreted, if the acid is only 2%.

Magnesium is excreted mainly in the urine, but some of it is re-absorbed and removed from the body with the feces.

Indications

• patients with chronic and acute ischemic heart disease (with unstable angina, acute myocardial infarction);
• in order to prevent the re-formation of blood clots;
• for the prevention of pathologies of the cardiovascular system (with acute coronary syndrome);
• the indication may be hypercholesterolemia, obesity, diabetes mellitus;
• patients under 55 years of age who had suffered a myocardial infarction in the past.

Forms of release

Tablets coated with 75 mg.

The tablets covered with a cover of 150 mg (Forte).

Instructions for use and dosing regimen

It is recommended to take Magnikor tablets whole, washing down if necessary. If desired, you can grind the tablet, chew it, or break it.

In acute or chronic form of ischemic heart disease, an initial dosage of 150 mg per day is recommended. The maintenance dose is 75 mg per day.

With angina and acute myocardial infarction, the daily dose equals 150 mg - 450 mg. It is recommended to start using Magnikor at the first symptoms.

For the prevention of thrombosis: the daily dose is 150 mg. The dose of support is 75 mg per day.

To prevent cardiac dysfunction, it is recommended to take 75 mg of the drug per day.

Side effect

• excessive bleeding due to suppression of platelet function with acetylsalicylic acid, sometimes reaching the latent bleeding;
• hypoprothrombinemia, neutropenia, thrombocytopenia, agranulocytosis, eosinophilia and aplastic anemia;
• headache;
• periodic sleep disorders;
• ringing and noise in the ears;
• intracranial hemorrhage;
• reversible hearing impairment up to deafness (at extremely high doses);
• patients with bronchial asthma often have bronchospasm;
• heartburn;
• reflux;
• nausea, vomiting;
• dyspeptic phenomena;
• erosion of the upper gastrointestinal tract;
• diarrhea;
• occurrence of ulcers of the mucosa of the upper esophagus;
• tarry stools;
• stomatitis;
• colitis;
• strictures;
• exacerbation of irritable bowel syndrome;
• ulcers of the lower parts of the digestive tract;
• reversible acute hepatitis, which occurs when the recommended dose is repeatedly exceeded;
• allergic reactions in the form of rash or urticaria, angioedema, hemorrhagic vasculitis, purpura;
• development of erythema multiforme;
• syndromes of Lyell and Stevens-Johnson;
• anaphylactic reactions;
• manifestations of allergic rhinitis;
• hypoglycemia.

Contraindications

• individual intolerance of components (such as salicylic acid and its derivatives) that make up the drug;
• stomach ulcer in the phase of exacerbation;
• increased risk of bleeding (vitamin K deficiency, anemia, thrombocytopenia);
• renal and hepatic insufficiency in severe form;
• heart failure;
• asthma or Quincke's edema on the background of taking non-steroidal anti-inflammatory drugs (NSAIDs) or salicylates in anamnesis;
• the last trimester of pregnancy;
• patients of childhood.

Application in pregnancy and lactation

Before using Magnikora, you should consult your doctor. If the expected beneficial effect of Magnikor therapy for a mother significantly exceeds the risk of a fetus, the drug may be used between 1 and 6 months of pregnancy. In this case, Magnikor is used only in minimal doses - up to 100 mg per day under the strict supervision of a physician.

Use in children

It is forbidden to use the drug in children.

special instructions

The use of Magnikor in long-term treatment or maintenance therapy is associated with some risks,if the drug is used simultaneously with non-steroidal anti-inflammatory drugs, or is used by elderly patients: in this case, the occurrence of gastrointestinal bleeding.

It is necessary to stop the drug in advance (3-4 days) if a surgical operation is planned in the near future.

Patients suffering from dyspepsia, mucosal integrity disorders, renal and hepatic insufficiency and allergic reactions to Magnikor components should also use this medication with extreme caution.

The use of salicylic acid and its derivatives, which are part of Magnikor, can lead to a decrease in the excretion of uric acid.

The effect of Magnikor's appointment to children has not been studied and its effectiveness for this age group has not been proven. There are also certain risks associated with the appointment of his children. Proceeding from this, Magnikor is categorically forbidden for use in children's age group.

Magnikor does not affect the speed of reaction and coordination. It is allowed to be used in conditions of the need to work with high-precision mechanisms and control of vehicles.

Drug Interactions

Magnikor with simultaneous administration potentiates the action of anticoagulants (such as warfarin, heparin, clopidogrel, fenprokumone) and hypoglycemic drugs. The drug suppresses the diuretic action of furosemide, inhibits the action of ACE, spironolactone.

It is not recommended to apply Magnikor simultaneously with NSAIDs. Antacid preparations worsen the absorption of this drug. The use of simultaneously with probenecid reduces the effect of both drugs.

Significant mutual influence of acetylsalicylic acid and magnesium was not noticed when using the drug. Perhaps this is due to the small amount of magnesium that is part of the composition.

Analogues of the drug Magnikor

Structural analogs for the active substance:

• Cardiomagn.

Analogues for the pharmacological group (antiaggregants):

• Agapurin;
• Agregal;
• Agrenoks;
• Agrilin;
• Aclotine;
• Alprostan;
• ASA cardio;
• Aspen;
• Aspirin Cardio;
• Acetylsalicylic acid;
• Ventavis;
• Godasal;
• Detromb;
• Dipyridamole;
• Doxylek;
• Ibustrin;
• Integrilin;
• Cardiomagnet;
• Clopidogrel;
• Clopilet;
• Coplawix;
• Xantinol nicotinate;
• Courantil;
• Lapal;
• Lopyrel;
• Myristin;
• Pentylin;
• Pentoxifylline;
• Plavix;
• Plagril;
• Ralofect;
• Target;
• Trental;
• Trombo ACC;
• Flexitale;
• Eikonol;
• Eifitol;
• Emoxipine.

Similar medicines:

Other medicines: